Finally, in vivo antitumor efficacy of ST7612AA1 was also observed against hematological tumor models, as shown by the potent antitumor activity (TVI=70%, P<0.01) in the AML model MV4;11 (Table 2) and in the GCB-DLBCL model DOHH2 bearing both MYC and BCL2 chromosomal rearrangement in which a significant delay in tumor progression (P<0.05) was observed (Supplementary Figure 4). Here, MYC is linked to acute myeloid leukemia.